坦索罗辛在晚期前列腺癌中应用的疗效及安全性分析

目的：评价并探讨坦索罗辛（Tarnsulosin，Harnal）治疗前列腺癌伴发下尿路症状（LUTS）的临床疗效及治疗的安全性。方法：2009年1月～2010年10月，收治存在LUTS、血压正常且国际前列腺症状评分（IPSS）均在20分以上的晚期前列腺癌患者76例，随机分为治疗组和对照组，均进行最大限度雄激素阻断治疗（MAB），同时治疗组联合应用超选择性αlA受体阻滞剂进行治疗。结果：治疗后4周和8周，治疗组的IPSS、生活质量指数评分、最大尿流率、前列腺体积、剩余尿量均较对照组有显著性改善（P〈0．05），血压变化的差异无统计学意义（P〉0．05）。治疗4周与8周比较无显著性差异（P〉0．05）。结论：MAB治疗可延长晚期前列腺癌患者的无进展生存期，而坦索罗辛可有效改善晚期前列腺癌患者下尿路症状，提高生活质量，且不良反应甚微。

Treatment Efficacy and Safety Analysis of Tamsulosin Application for Advanced Prostate cancer

Objective：To evaluate and investigate the treatment efficacy and safety of tamsulosin application for the treatment of advanced prostate cancer associated with lower urinary tract symptoms（LUTS）. Methods：January 2009-October 2010,76 patients with advanced prostate cancer in our department who have LUTS, normal blood pressure and whose international prostate symptom score （IPSS） were more than 20 points, are randomly divided into treatment group （T） and control group （C）. Both groups were treated with Maximal androgen blockade （MAB）, and T group also combined with super-selective αlA receptor antagonist for treatment. Results： after 4 weeks and 8 weeks treatment,international prostate symptom score （IPSS）, quality of life index scoresmaximum urinary flow rate, prostate volume （V）, residual urine volume （Ru） were much improvement in T group compared with the C group（P〈0.05）, Blood pressure variation was no significant difference（P〉0.05）. Treatment for 4 weeks and 8 weeks showed no significant difference（P〉0.05）. Conclusions..MAB treatment may prolong progression-free survival of patients of advanced prostate cancer, tamsulosin may be effective in improving symptoms and quality of life in these patients who had LUTS with very little adverse reactions.